Abstract 119P
Background
Gastric cancer (GC) remains the fifth most common malignancy worldwide accounting for over 1 million new cases and an estimated 769,000 deaths by 2020. Nearly 40% of the global GC cases occur in China, and the 5-year overall survival rate is less than 50%. Lymph node metastases (LNM) is an independent risk factor for prognosis and determines which treatments can be used in GC. LNM plays a crucial gateway role in cancer spread, but the underlying roles of LNM remain controversial, and there is no worldwide consensus. Therefore, the aim of this study was to investigate the clinical perspective and significance of LNM in GC via a retrospective study.
Methods
This study was performed on 129 patients who had gastric cancer with lymphadenectomy for the radical cure, whose specimens were obtained during surgery. Dissected lymph nodes were collected in groups and histopathological studies were performed to detect the lymph node metastasis and metastatic lymph node ratio (MLR). We also analyzed the relationships between rates of lymph node metastasis and tumor diameters, tumor localization, infiltrating depth, histological category, Borrmann typing, and so on.
Results
Among 129 patients with gastric cancer, lymph node metastases were found in 80 patients (62.02%) with a total collection of 3295 lymph nodes and an average of 25.54 lymph nodes per patient. The number of lymph nodes with metastasis was 889. Lymph node metastasis was associated with tumor size, the depth of invasion, Borrmann type, location and histological type. There were correlations between the total number of lymph nodes from 129 gastric cancer patients, metastatic lymph node numbers and MLR. Analysis of the survival curve showed that the survival time and rate had a negative correlation with the TNM stage and MLR.
Conclusions
According to the clinical and pathological factors, the characteristics of lymph node metastasis by groups and stations in different areas, and properly choosing and extending the extent of lymph node resection, the objective of the radical cure for gastric cancer could be achieved individually when radical lymphadenectomy is performed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Technology Innovation Guidance Special Program of Shaanxi Province (2022QFY01-08), Key Research and Development Program of Shaanxi Province (2021SF-288), Natural Science Basic Research Program of Shaanxi Province (2020JQ-950, 2022JM-570), Health Research Program of Shaanxi Province (2022D002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02
120P - Clinical implication of DNA damage response gene in advanced gastric cancer stage IV and recurrent gastric cancer patients after gastrectomy treated palliative chemotherapy
Presenter: In Gyu Hwang
Session: Poster viewing 02
121P - Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
Presenter: Amrith B P
Session: Poster viewing 02
122P - Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Presenter: Amrith B P
Session: Poster viewing 02
123P - Sarcomatoid carcinoma of gall bladder: A series of 14 cases from a single tertiary-care oncology centre
Presenter: Subhash Yadav
Session: Poster viewing 02
124P - Clinical profile and treatment outcomes of hepatocellular carcinoma from a tertiary care hospital in South India: A retrospective study
Presenter: Gayathri Nair
Session: Poster viewing 02
125P - A parametric network meta-analysis of PD-1 inhibitors in second-line treatment for advanced esophageal squamous cell carcinoma
Presenter: Shubhram Pandey
Session: Poster viewing 02
126P - Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Presenter: Keitaro Shimozaki
Session: Poster viewing 02
127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Presenter: Jirapat Wonglhow
Session: Poster viewing 02
128P - Survival outcome of gastric cancer patients in a tertiary care center: A 10-year single center retrospective study
Presenter: Dawn Lynn Guardiario
Session: Poster viewing 02